688670 Stock Overview
Engages in the scientific research, production, operation, and service of human vaccines.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Jiangsu Gdk Biological Technology Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥11.34 |
52 Week High | CN¥39.13 |
52 Week Low | CN¥10.46 |
Beta | 0.20 |
11 Month Change | 2.62% |
3 Month Change | -36.04% |
1 Year Change | -63.24% |
33 Year Change | -81.46% |
5 Year Change | n/a |
Change since IPO | -80.85% |
Recent News & Updates
Shareholder Returns
688670 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -2.3% | -2.2% | -0.6% |
1Y | -63.2% | -22.2% | -19.0% |
Return vs Industry: 688670 underperformed the CN Biotechs industry which returned -22.4% over the past year.
Return vs Market: 688670 underperformed the CN Market which returned -19% over the past year.
Price Volatility
688670 volatility | |
---|---|
688670 Average Weekly Movement | 6.5% |
Biotechs Industry Average Movement | 5.5% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 688670's share price has been volatile over the past 3 months.
Volatility Over Time: 688670's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 451 | n/a | www.gdkbio.com |
Jiangsu Gdk Biological Technology Co., Ltd engages in the scientific research, production, operation, and service of human vaccines. The company offers quadrivalent influenza virus split vaccines. Its product pipeline has coverage for the prevention of principal infectious diseases, including influenza, rabies, chickenpox, herpes zoster, and pneumonia.
Jiangsu Gdk Biological Technology Co., Ltd Fundamentals Summary
688670 fundamental statistics | |
---|---|
Market cap | CN¥1.40b |
Earnings (TTM) | -CN¥128.83m |
Revenue (TTM) | CN¥33.39m |
41.8x
P/S Ratio-10.8x
P/E RatioIs 688670 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688670 income statement (TTM) | |
---|---|
Revenue | CN¥33.39m |
Cost of Revenue | CN¥70.82m |
Gross Profit | -CN¥37.43m |
Other Expenses | CN¥91.40m |
Earnings | -CN¥128.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
Earnings per share (EPS) | -1.05 |
Gross Margin | -112.10% |
Net Profit Margin | -385.83% |
Debt/Equity Ratio | 5.0% |
How did 688670 perform over the long term?
See historical performance and comparison